Skip to main content
Passa alla visualizzazione normale.

CATERINA MARIA GAMBINO

COVID-19 and Alzheimer's Disease

  • Authors: Marcello Ciaccio; Bruna Lo Sasso; Concetta Scazzone; Caterina Maria Gambino; Anna Maria Ciaccio; Giulia Bivona; Tommaso Piccoli; Rosaria Vincenza Giglio; Luisa Agnello
  • Publication year: 2021
  • Type: Review essay (rassegna critica)
  • OA Link: http://hdl.handle.net/10447/486997

Abstract

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a neurotropic virus with a high neuroinvasive potential. Indeed, more than one-third of patients develop neurological symptoms, including confusion, headache, and hypogeusia/ageusia. However, long-term neurological consequences have received little interest compared to respiratory, cardiovascular, and renal manifestations. Several mechanisms have been proposed to explain the potential SARS-CoV-2 neurological injury that could lead to the development of neurodegenerative diseases, including Alzheimer's Disease (AD). A mutualistic relationship between AD and COVID-19 seems to exist. On the one hand, COVID-19 patients seem to be more prone to developing AD. On the other hand, AD patients could be more susceptible to severe COVID-19. In this review, we sought to provide an overview on the relationship between AD and COVID-19, focusing on the potential role of biomarkers, which could represent precious tool for early identification of COVID-19 patients at high risk of developing AD.